01/07/2010 Identified the first genetic variant that predicts response to treatment of hepatitis C 01/07/2010 Vall d’Hebron Research Institute has participated in a study that has identified the first genetic variant of hepatitis C (IL28B), able to predict whether a patient will have a good or poor response to treatment. "The IL28B allows us to differentiate very well between patients who will do well with treatment and patients who need more medication or combination therapy. For the first time we have a genetic marker to differentiate patients with chronic hepatitis C",says Dr. Rafael Esteban Mur, Chief of Hepatology at the Hospital de la Vall d'Hebron, and the only Spanish signing of this study, led by Dr.JC McHutchison of Duke Clinical Research Institute, Durham, North Carolina, published in the journal Gastroentergology. Vall d’Hebron Research Institute has participated in a study that has identified the first genetic variant of hepatitis C (IL28B), able to predict whether a patient will have a good or poor response to treatment. "The IL28B allows us to differentiate very well between patients who will do well with treatment and patients who need more medication or combination therapy. For the first time we have a genetic marker to differentiate patients with chronic hepatitis C",says Dr. Rafael Esteban Mur, Chief of Hepatology at the Hospital de la Vall d'Hebron, and the only Spanish signing of this study, led by Dr.JC McHutchison of Duke Clinical Research Institute, Durham, North Carolina, published in the journal Gastroentergology. Twitter LinkedIn Facebook Whatsapp
